Crispr Therapeut Stock Price, News & Analysis

Summary not available.

CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in the 22nd Annual Needham Healthcare Conference, taking place virtually from April 17-20, 2023. The company's CEO, Sam Kulkarni, will present during a fireside chat on April 19, 2023, at 3:00 p.m. ET. The session will be accessible via a live webcast on the company's Investors page, and will be available for replay for 14 days post-event. CRISPR Therapeutics is recognized for its innovative approach in gene editing, leveraging the CRISPR/Cas9 technology to develop treatments for various serious diseases, including hemoglobinopathies, oncology, and rare diseases, in collaboration with partners like Bayer and Vertex Pharmaceuticals.

Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) aimed at sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The applications, submitted to the FDA, include requests for Priority Review, potentially expediting the review period to eight months. The filings are supported by ongoing Phase 3 clinical studies and previous data presented at the ASH Annual Meeting in December 2022. Both companies highlight their commitment to the advancement of CRISPR technology in treating genetic diseases.

CRISPR Therapeutics (Nasdaq: CRSP) announced the resignation of Brad Bolzon, Ph.D., from its Board of Directors after nearly ten years. Bolzon's contributions were pivotal in shaping the company's vision and strategy, with management acknowledging his strategic insights in advancing gene editing technology. The company focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform, targeting serious diseases across multiple therapeutic areas. CRISPR Therapeutics has established strategic partnerships with leading firms such as Bayer and Vertex Pharmaceuticals.

Vertex Pharmaceuticals has secured a non-exclusive licensing agreement with CRISPR Therapeutics for its CRISPR/Cas9 technology, aiming to enhance the development of hypoimmune cell therapies for Type 1 Diabetes (T1D). Vertex will pay $100 million upfront, with potential additional payments up to $230 million based on future achievements. This collaboration builds on Vertex's existing programs, including VX-880, which has shown clinical proof of concept. Both companies express optimism about accelerating the creation of insulin-producing cells, though challenges and risks remain in clinical validation.

CRISPR Therapeutics (Nasdaq: CRSP) announced the presentation of preclinical data at the AACR 2023 Annual Meeting in Orlando, FL, scheduled for April 14-19, 2023. The presentation titled CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic CAR T cells highlights novel edits that enhance potency and efficacy for treating lymphoid and solid tumors.

This session will take place on April 16, 2023, from 1:25 to 1:40 p.m. ET at the Tangerine Ballroom 2. Data will be under embargo until the session starts, with a copy of the presentation available post-session on their official website.

CRISPR Therapeutics (Nasdaq: CRSP) has appointed Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. Dr. Prasad brings extensive experience from William Blair & Company, where he focused on cell and gene therapy sectors. He succeeds Brendan Smith, who is departing for new opportunities. Dr. Prasad's background includes leading biotechnology analysis and consulting for regulatory bodies. CEO Samarth Kulkarni highlighted Dr. Prasad's vital expertise and market relationships as significant assets for the company. CRISPR Therapeutics continues to advance its gene editing technologies and strategic partnerships, positioning itself within the biopharmaceutical landscape.

CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 10:30 a.m. ET. This event highlights the company’s focus on transformative gene-based medicines for serious diseases.

A live webcast will be available on the company's Investors website, with an archived replay accessible for 14 days post-event. CRISPR Therapeutics utilizes its proprietary CRISPR/Cas9 platform to develop treatments across various disease areas, including oncology and rare diseases, in collaboration with leading partners.

CRISPR Therapeutics (CRSP) reported significant advancements in its product pipeline, including completed regulatory submissions for exa-cel for transfusion-dependent beta thalassemia and sickle cell disease in Europe, with a U.S. BLA submission expected by Q1 2023. The company is also advancing clinical trials for CAR T therapies CTX110 and CTX130, along with new candidates CTX112 and CTX131. Financially, CRISPR ended 2022 with $1.87 billion in cash but reported a net loss of $650.2 million for the year, marking a significant contrast to the $377.7 million net income in 2021.